RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,120,326.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total value of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total value of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Down 1.3 %

Shares of NASDAQ RXST traded down $0.65 during midday trading on Tuesday, hitting $49.61. The company had a trading volume of 211,049 shares, compared to its average volume of 476,145. The business has a 50-day simple moving average of $51.99 and a two-hundred day simple moving average of $53.88. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -39.89 and a beta of 1.20.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. During the same quarter in the previous year, the firm earned ($0.40) earnings per share. The firm’s revenue for the quarter was up 67.6% compared to the same quarter last year. On average, equities analysts forecast that RxSight, Inc. will post -0.81 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on RXST. Wells Fargo & Company dropped their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. BTIG Research raised their price target on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Stifel Nicolaus reduced their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight presently has an average rating of “Buy” and an average target price of $60.14.

Institutional Investors Weigh In On RxSight

Hedge funds have recently modified their holdings of the business. CWM LLC increased its position in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the period. Quest Partners LLC bought a new stake in RxSight in the 2nd quarter valued at $41,000. Larson Financial Group LLC bought a new stake in shares of RxSight during the 1st quarter valued at $51,000. Amalgamated Bank lifted its position in shares of RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after buying an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of RxSight during the 2nd quarter worth $156,000. 78.78% of the stock is owned by institutional investors.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.